

Morgan Lewis



Emerging Life Sciences Companies
second edition

Emerging Life Sciences Companies Deskbook

second edition

© Morgan, Lewis & Bockius LLP, Emerging Life Sciences Companies Deskbook, all rights reserved.
This deskbook is provided as a general informational service to clients and friends of Morgan Lewis.
It should not be construed as, and does not constitute, legal advice on any specific matter.

Table of Contents

Introduction		iii
Section I		
Structuring and Financing a Life Sciences Company		
Chapter 1	Choosing the Ideal Structure for Your Business Entity	3
Chapter 2	Realizing Value From New Venture Spin-outs	10
Chapter 3	Corporate Governance Issues	16
Chapter 4	How to Be Touched by an Angel	22
Chapter 5	Preparing a Venture Capital Term Sheet	27
Section II		
Intellectual Property Strategy		
Chapter 6	Intellectual Property Protection	45
Chapter 7	Freedom to Operate	50
Chapter 8	Checklist for Planning and Conducting an Effective FTO Search	58
Chapter 9	Conducting and Managing a Patent FTO Search	64
Chapter 10	Antitrust Aspects of Patent Pooling in the Biotech Context	75
Section III		
Building a Team and Finding a Location		
Chapter 11	Employment Law Issues for Emerging Companies	81
Chapter 12	Section 409A of the Internal Revenue Code	98
Chapter 13	Summary of Equity-Based Executive Compensation Programs	99
Chapter 14	Real Estate Leasing Tips for Life Sciences Companies	106
Section IV		
Regulatory Approval, Pricing, and Reimbursement, and Healthcare Fraud and Abuse		
Chapter 15	Expanding a Pharma/Biotech Business in the United States: Regulatory and Competition Issues	111
Chapter 16	Risk Management for Drugs and Biologics in the United States	117
Chapter 17	Medicare Coverage of Drugs and Devices Under Medicare Parts A and B	133
Chapter 18	Medicare Reimbursement for Drugs and Devices	139
Chapter 19	What Medical Technology Companies Should Know About Program Integrity Issues Arising from Reimbursement and Marketing	149
Chapter 20	Medicare Act of 2003 Provides New Competitive Landscape for the Pharmaceutical Industry	153
Chapter 21	FDA Due Diligence for Pharmaceuticals and Biologics Products	157

Section V

Strategic Alliances, Collaborations, and Outsourcing

Chapter 22	Protective Provisions in Biotech Strategic Alliances	167
Chapter 23	Strategies for Preparing and Negotiating a Strategic Alliance with Big Pharma	172
Chapter 24	Licensing in the Pharmaceutical Industry: Strategies and Questions Regarding Antitrust Premerger Notification	181
Chapter 25	Outsourcing in the Pharmaceutical Industry	189
Chapter 26	Key Contract Provisions for Supply and Manufacturing Agreements	194
Chapter 27	Key Contract Provisions for License Agreements	201

Section VI

Preparing for Liquidity Events and Growth by Acquisition

Chapter 28	Outline of Issues for a Biotech Company to Consider in Preparing for an IPO	209
Chapter 29	Overcoming the Unique Challenges in Private vs. Public Life Sciences M&A	217
Chapter 30	Issues That Must Be Addressed in a Life Sciences M&A	225
Chapter 31	Key Contract Provisions for Asset Purchase Agreements	231
Chapter 32	Acquiring Intellectual Property: Potential Pitfalls	240

Section VII

International Expansion

Chapter 33	Bringing a Drug to Market in the European Union: Regulatory, Corporate, and Taxation Issues	245
Chapter 34	Doing Business in China	262
Chapter 35	Regulation of Pharmaceutical Products and Medical Devices in Japan*	284
Chapter 36	Expanding to the United States: Issues for a Biotech Company to Consider in Preparing for U.S. Market Entry	289

Acknowledgements	295
-------------------------	-----

Section V Supplement

Strategic Alliances, Collaborations, and Outsourcing

Pharmaceutical Products Liability Litigation	301
--	-----

*This chapter was written by the lawyers of Morgan Lewis-TMI, a joint venture in Japan.